Loading
Sentiment · FY2026 Q1
What companies say about each other on earnings calls — extracted verbatim from public transcripts. Mentions from the newest quarter are a Pro feature.
“Lilly's AI factory for drug discovery, the pharmaceutical industry's most powerful data center.”
Eli Lilly is building an NVIDIA-powered AI factory for drug discovery, the pharma industry's most powerful data center.
“was shown in Lilly's SURMOUNT-OSA study to be the best outcome in their own analysis, is one that we would encourage.”
ResMed cited Lilly's SURMOUNT-OSA study showing GLP-1 plus CPAP combination therapy as the best outcome, framing Lilly's drug as a demand tailwind rather than a threat.
“Lilly and Novo seem to be really expanding their cash pay GLP-1 programs via LillyDirect to NovoCare, which obviates the need for PA.”
Lilly is rapidly expanding its LillyDirect cash-pay GLP-1 channel, which bypasses the prior-authorization process that underpins a portion of McKesson's Prescription Technology Solutions revenue, signaling a growing direct-to-consumer threat to McKesson's access-services business model.
“And so I think it's more likely that Zepbound or that type of a drug would be used as that third-tier versus an Apnimed which only half treats the apnea.”
ResMed's CEO frames Lilly's Zepbound (GLP-1) as displacing emerging oral drug candidates like Apnimed for third-tier sleep apnea therapy, citing its broader metabolic and cardiovascular benefits — a signal of Zepbound's expanding therapeutic reach beyond weight loss.
“And we've won significant global mandates this year from firms, including Eli Lilly and Shell.”
Goldman Sachs won a significant outsourced-CIO/solutions mandate from Eli Lilly, a read-through that Lilly is outsourcing investment management.
“our important collaboration with Lilly and its TUNE lab initiative.”
Eli Lilly is co-funding access to Revvity's Signals platform and providing Synthetica modeling credits via its TuneLab AI-models initiative, embedding Lilly's models in Revvity's drug-discovery workflow.
“compete in that ultra-high efficacy tier with agents like Lilly's g g g”
An analyst frames Pfizer's obesity assets as competing with Lilly's high-efficacy agents, positioning Lilly as the key obesity competitor.
“And we're seeing big pharma making nice moves. Novo Nordisk, J&J, Eli Lilly.”
MLM names Eli Lilly among pharma companies building new facilities, a read-through on Lilly's continued domestic manufacturing capex.
“Lilly will come out with a pill form of their own sometime in probably Q1, Q2.”
Discussing GLP-1 adoption risk to restaurant traffic, McDonald's noted Eli Lilly is expected to launch its own oral GLP-1 pill in Q1/Q2; a timing read-through on Lilly's oral obesity drug.
“we also have some $6,000,000,000 Eli Lilly project here in Alabama that is kicking off.”
Vulcan cites a $6B Eli Lilly manufacturing project in Alabama as an aggregate-intensive private non-residential demand driver, signaling Lilly capacity expansion.
“the over $15 billion investment that Eli Lilly has referenced for the Greater Houston area is pretty incredible.”
CenterPoint cites Eli Lilly's $15B+ Greater Houston investment as a driver of new industrial load and thousands of jobs in its service territory, a positive read-through for Lilly's manufacturing expansion.
“the $3,500,000,000 advanced manufacturing investment by Eli Lilly, announced earlier this month right here in Allentown, Pennsylvania.”
Eli Lilly's $3.5B advanced manufacturing investment in Allentown is cited as a major economic-development project driving new load in PPL's Pennsylvania service territory, a positive read-through for Lilly's US manufacturing expansion.
“We're very encouraged by what we're seeing with oral Wegovy as it validates our belief that there's a substantial number of people with overweight and obesity who have been sitting on the sidelines waiting for an oral option.”
Lilly reads competitor Novo Nordisk's oral Wegovy launch as market-expansionary (mostly new starts), validating demand for oral GLP-1s ahead of its own orforglipron.
“we recently announced a new collaboration with NVIDIA to open a co-innovation AI lab. This project will combine Lilly's scientific expertise with NVIDIA's leading technology to accelerate drug discovery.”
Eli Lilly announced a co-innovation AI lab collaboration with NVIDIA to accelerate drug discovery.
“being able to pick up your Zepbound vial at a local Walmart, which we announced yesterday”
Lilly announced a partnership letting patients pick up Zepbound vials at Walmart, expanding its direct-to-consumer distribution footprint.
“probably smart of Cigna to make this first move to recoup market share or gain market share.”
Lilly's CEO applauds Cigna's move to replace drug rebates with GPO fees, framing it as favorable for innovators, patients and payers and hoping other PBMs follow.
“While the impact of the CVS template formulary change was disruptive to patients and physicians, the impact on Zepbound performance was modest.”
CVS's template formulary change (dropping/altering Zepbound coverage) disrupted patients and physicians, though Lilly says the effect on Zepbound was modest and share recovered.
“with Novo's sema, we get an IRA negotiated price within the next month.”
An analyst frames Novo Nordisk's semaglutide as the key GLP-1 competitor whose upcoming IRA-negotiated Medicare price could influence pricing across the class; Lilly stresses tirzepatide's head-to-head superiority.
“And Verve Therapeutics, which adds new genetic medicines for cardiovascular disease with potential to only be administered once in a person's lifetime”
Lilly acquired Verve Therapeutics, adding one-time genetic medicines for cardiovascular disease (PCSK9, ANGPTL3 programs).
“We announced and closed the acquisition of SiteOne Therapeutics, which expands Lilly's pain portfolio and adds a clinical-stage non-opioid pain program to our mix”
Lilly closed its acquisition of SiteOne Therapeutics, adding a clinical-stage non-opioid pain program (Nav1.8 inhibitor STC-004).
“Canadian generics for Novo's semaglutide, they're likely to launch in early '26”
Canadian generic semaglutide (Novo Nordisk) is expected to launch in early 2026, raising a potential cash-pay competitive threat in the incretin market.
“which clearly looks efficacious but maybe a touch below Wegovy”
Analyst notes orforglipron's weight-loss efficacy looks slightly below Novo Nordisk's Wegovy, a key competitive benchmark in obesity.
“we are seeing new benefit designs, like, for instance, Evernorth, a cap on out-of-pocket for employees that make the prior authorization simplified”
Cigna's Evernorth introduced a benefit design capping employee out-of-pocket costs and simplifying prior authorization, which could grow employer opt-in coverage for Zepbound.
“effective July 1, the CVS pharmacy benefit manager began excluding Zepbound as an offering for patients on its template formulary insurance plans”
CVS Caremark excluded Zepbound from its template formulary as of July 1; Lilly expects it to be a headwind to Zepbound volume growth in Q3.
| Analyst | Firm | Questions (Challenge)Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Alex Hammond | Wolfe Research | 6 (17%) |
| Terence Flynn | Morgan Stanley | 6 (0%) |
| Chris Schott | JPMorgan | 6 (17%) |
| Umer Raffat | Evercore ISI | 6 (67%) |
| Courtney Breen | Bernstein | 6 (17%) |
| Geoff Meacham | Citigroup | 6 (0%) |
| Mohit Bansal | Wells Fargo | 6 (0%) |
| Steve Scala | TD Cowen | 5 (80%) |
| Jim Shin | Deutsche Bank | 5 (0%) |
| Dave Risinger | Leerink Partners | 5 (20%) |
| Firm | Analysts | Questions (Challenge)Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Guggenheim | 2 | 6 (0%) |
| JPMorgan | 1 | 6 (17%) |
| BMO Capital Markets | 2 | 6 (0%) |
| Citigroup | 1 |
Revenue grew 43% in Q4 with EPS of $7.54 as the incretin portfolio continued dominating the GLP-1 class with Zepbound holding nearly 70% share of new obesity prescriptions. Orforglipron submission readiness, the ATTAIN-MAINTAIN weight maintenance study, and retatrutide TRIUMPH-4 data all advanced the pipeline. Management introduced FY2026 guidance of $80-$83 billion revenue and $33.50-$35 EPS.
Pricing | Demand | Innovation & R&D | Product Launch | Competitive Dynamics | Regulation Policy | Geographic Expansion | Margin | |
|---|---|---|---|---|---|---|---|---|
| 2024Q4 | 3 | 6 | 7 | 8 | 3 | 2 | 1 | 1 |
| 2025Q1 | 9 | 4 | 6 | 4 | 6 | 4 | 1 | |
| 2025Q2 | 7 | 3 | 6 | 2 | 4 | 4 | ||
| 2025Q3 | 5 | 4 | 4 | 4 | 3 | 2 | 2 | |
| 2025Q4 | 3 | 6 | 3 | 4 | 1 | 4 | 1 | |
| 2026Q1 | 3 | 6 | 1 | 3 | 4 | 3 | 1 | 1 |
| '24Q4 | '25Q1 | '25Q2 | '25Q3 | '25Q4 | '26Q1 | |
|---|---|---|---|---|---|---|
| Pricing | 3 | 9 | 7 | 5 | 3 | 3 |
| Demand | 6 | 4 | 3 | 4 | 6 | 6 |
| Innovation & R&D | 7 | 6 | 6 | 4 | 3 | 1 |
| Product Launch | 8 | 4 | 2 | 4 | 4 | 3 |
| Competitive Dynamics | 3 | 6 | 4 | 3 | 1 | 4 |
| Regulation Policy | 2 | 4 | 4 | 2 | 4 | 3 |
| Geographic Expansion | 1 | 2 | 1 | 1 | ||
| Margin | 1 | 1 | 1 |
| 6 (0%) |
| Bernstein | 1 | 6 (17%) |
| Evercore ISI | 1 | 6 (67%) |
| Goldman Sachs | 2 | 6 (0%) |
| Morgan Stanley | 1 | 6 (0%) |
| Company | Score | Trend | Rev YoY |
|---|---|---|---|
LLY Lilly (Eli) | 10 | +55.5% | |
| ABBV AbbVie | 9 | +12.4% | |
| AMGN Amgen Inc. | 8 | +5.8% | |
| BIIB Biogen | 4 | +1.9% | |
| BMY Bristol Myers Squibb | 4 | +2.6% | |
| GILD Gilead Sciences | 8 | +4.4% | |
| JNJ Johnson & Johnson | 7 | +10.1% | |
| MRK Merck & Co., Inc. | 7 | +4.3% | |
| PFE Pfizer | 5 | +5.4% |